HIV Glasgow 2024

HIV Glasgow 2024
November 10-13, 2024
Glasgow, Scotland

HIV Glasgow 2024 .

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (13)

    Pharmacokinetic/pharmacodynamic and resistance analyses of GS-1720, a once-weekly oral integrase strand transfer inhibitor

    • Author(s): Falkard, B
    • gs-1720
    • HIV / AIDS
    • Poster

    Safety and immunogenicity of GS-1966+GS-1144 vaccines in virally suppressed adults living with HIV-1: a phase 1b, randomised, placebo-controlled study

    • Author(s): Benson, C
    • gs-1966
    • HIV / AIDS
    • Poster

    Pharmacokinetics of oral islatravir (ISL) plus lenacapavir (LEN) given once weekly in an open- label, active-controlled, phase 2 study of virologically suppressed people with HIV-1

    • Author(s): Longo, D
    • lenacapavir-in-combination-with-bnabs
    • HIV / AIDS
    • Poster

    Metabolic changes at 48 weeks in virologically suppressed people with HIV switching from complex antiretroviral regimens to bictegravir plus lenacapavir: ARTISTRY-1 trial

    • Author(s): Prelutsky, D
    • lenacapavir-in-combination-with-bictegravir
    • HIV / AIDS
    • Poster

    4-year outcomes from the BICSTAR study: real-world use of B/F/TAF in TN and TE PWH in Canada, France and Germany

    • Author(s): Wong, A
    • biktarvy
    • HIV / AIDS
    • Poster

    Once-weekly islatravir plus lenacapavir in virologically suppressed pwh: week 48 safety, efficacy, and metabolic changes

    • Author(s): Colson, A
    • lenacapavir-in-combination-with-bnabs
    • HIV / AIDS
    • Oral

    Twice-yearly lenacapavir prep in cisgender gay men, transgender women and men, and gender-diverse people (purpose 2)

    • Author(s): Kelley, C
    • sunlenca
    • HIV / AIDS
    • Oral

    Effect of acid reducing agents on the pharmacokinetics of oral GS-4182

    • Author(s): Shaik, N
    • gs-4182
    • HIV / AIDS
    • Poster

    Pharmacokinetic (PK) analysis of oral once-daily bictegravir (BIC) plus lenacapavir (LEN) administered separately (BIC 75mg + LEN 25mg; BIC 75mg + LEN 50mg) and as a single-tablet BIC/LEN 75/50mg fixed-dose combination (FDC)

    • Author(s): Arora, P
    • lenacapavir-in-combination-with-bictegravir
    • HIV / AIDS
    • Poster

    Real-world effectiveness in treatment-experienced PWH switching to B/F/TAF with distinct patterns of self-reported adherence

    • Author(s): Boffito, M
    • biktarvy
    • HIV / AIDS
    • Poster

    Bictegravir/emtricitabine/tenofovir alafenamide (b/f/taf) in treatment-naïve people with both hiv-1 and hepatitis b: 3-year outcomes from ALLIANCE

    • Author(s): Avihingsanon, A
    • biktarvy
    • HIV / AIDS
    • Poster

    Efficacy and safety analysis of lenacapavir with broadly neutralising antibodies, teropavimab and zinlirvimab, in people with HIV-1 highly sensitive to one or both broadly neutralising antibodies

    • Author(s): Cook, P
    • lenacapavir-in-combination-with-bnabs
    • HIV / AIDS
    • Oral

    Persistence in use of twice-yearly lenacapavir versus daily oral prep in the purpose 1 phase 3 trial

    • Author(s): Bekker, L
    • sunlenca
    • HIV / AIDS
    • Oral